Lower Healthcare Costs Associated with the Use of a Single-Pill ARV Regimen in the UK, 2004–2008
Open Access
- 30 October 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10), e47376
- https://doi.org/10.1371/journal.pone.0047376
Abstract
Investigate the cost and effects of a single-pill versus two- or three pill first-line antiretroviral combinations in reducing viral load, increasing CD4 counts, and first-line failure rate associated with respective regimens at 6 and 12 months. Patients on first-line TDF+3TC+EFV, TDF+FTC+EFV, Truvada®+EFV or Atripla® between 1996–2008 were identified and viral load and CD4 counts measured at baseline, six and twelve months respectively. Factors that independently predicted treatment failure at six and twelve months were derived using multivariate Cox's proportional hazard regression analyses. Use and cost of hospital services were calculated at six and twelve months respectively. All regimens reduced viral load to below the limit of detection and CD4 counts increased to similar levels at six and twelve months for all treatment regimens. No statistically significant differences were observed for rate of treatment failure at six and twelve months. People on Atripla® generated lower healthcare costs for non-AIDS patients at £5,340 (£5,254 to £5,426) per patient-semester and £9,821 (£9,719 to £9,924) per patient-year that was £1,344 (95%CI £1,222 to £1,465) less per patient-semester and £1,954 (95%CI £1,801 to £2,107) less per patient-year compared with Truvada®+EFV; healthcare costs for AIDS patients were similar across all regimens. The single pill regimen is as effective as the two- and three-pill regimens of the same drugs, but if started as first-line induction therapy there would be a 20% savings on healthcare costs at six and 17% of costs at twelve months compared with Truvada®+EFV, that generated the next lowest costs.This publication has 26 references indexed in Scilit:
- Counting the Cost of Not Costing HIV Health Facilities AccuratelyPharmacoEconomics, 2012
- Discontinuation of Atripla as first-line therapy in HIV-1 infected individualsAIDS, 2012
- Adherence to Antiretroviral Treatment and Correlation with Risk of Hospitalization among Commercially Insured HIV Patients in the United StatesPLOS ONE, 2012
- The Cost-Effectiveness of Early Access to HIV Services and Starting cART in the UK 1996–2008PLOS ONE, 2011
- Cost-effectiveness analysis of initial HIV treatment under Italian guidelinesClinicoEconomics and Outcomes Research, 2011
- Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006PLOS ONE, 2011
- Rising Population Cost for Treating People Living with HIV in the UK, 1997-2013PLOS ONE, 2010
- A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed peopleAIDS, 2010
- One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjectsPatient Preference and Adherence, 2010
- Cost-Effectiveness of Highly Active Antiretroviral Therapy in South AfricaPLoS Medicine, 2005